vasodilators.47 Infants with alveolar-arterial oxygen gradients (A-aDO2) of 82-46 kPa all die, and among those with A-aDO2 of 79-8 kPa or more for 12 hours the mortality was 94%. 5 Clinical presentation Persistent pulmonary hypertension of the newborn may present with severe hypoxia, severe acidosis, tachypnoea, tricuspid or mitral regurgitation, patent ductus arteriosus, hypovascularity on the chest radiograph, relatively clear lung fields and no anatomical cardiac lesions. The patient may develop right ventricular heave, electrocardiographic changes of myocardial ischaemia, and right ventricular overload. The disease may present immediately after birth-for example, in asphyxiated infants or those with diaphragmatic hernia with severe lung hypoplasia. It may present after [4] [5] [6] [7] [8] [9] [10] [11] [12] hours (subacute)-for example, in infants with meconium aspiration syndrome, or it may present after [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] hours (late)-for example, infants with sepsis and those with progressive airways obstruction.47 9 
Treatment
The aetiological diversity of the disease means that no single treatment will be uniformly effective. No enzymes and is a necessary cofactor for ATPase. Thus magnesium is a vital cofactor in the maintenance of several energy demanding processes at the cellular level such as oxidative phosphorylation, neuromuscular excitability, and muscle contraction.
Lipman et al have shown that a continuous intravenous infusion of magnesium sulphate can control sympathetic crises and suppress the release of catecholamines.37 Magnesium sulphate also activates adenyl cyclase, which plays a part in the synthesis of cyclic AMP.38 increases in the amounts of cyclic AMP in smooth muscle promote relaxation by inhibiting the activity of myosin light chain kinase caused by accumulation of calcium by the sarcoplasmic reticulum, and resulting in a fall in intracellular free calcium to concentrations at which the myosin light chain kinase is not active. 39 The effect of magnesium on cyclic AMP is of particular interest because there are data that suggest that increased cyclic AMP concentrations promote vasodilation.40 Magnesium sulphate causes peripheral arteries to dilate by various mechanisms. An indirect curare like action retards the release of acetylcholine and interferes with transmission at the neuromuscular junction and sympathetic ganglia. A direct action of the cation reduces the responsiveness of smooth muscle to sympathomimetic amines as well as to nonsympathomimetic vasopressors.37 41A2 After an episode of ischaemic anoxia, concentrations of arachidonic acid rise rapidly in anoxic neurons. 43 The influx of calcium ions to anoxic arterioles results in vascular spasm.44 In animal studies, magnesium antagonises calcium ion entry thereby promoting vasodilatation and alleviating the effect of severe hypoxia on the brain, liver, and kidneys.
Thrombosis and consumption of platelets occur in small blood vessels in pulmonary hypertension.3 19 Magnesium has an antithrombotic effect which-at least theoretically-has a role in the treatment of pulmonary hypertension. 49 In patients with severe hypertension of pregnancy, Cotton et al found that both systemic vascular resistance and pulmonary vascular resistance fell after magnesium sulphate was given, and by 30 minutes had returned to baseline values. 50 McMurtry et al showed in isolated rat lungs that calcium antagonists inhibited hypoxic pulmonary vasoconstriction and that the hypoxic mechanism was critically dependent on the transmembrane influx of extracellular calcium.5' Similarly, inhibiting hypoxic vasoconstriction in dogs by increased plasma concentrations of magnesium chloride52 was possibly related to calcium antagonism by magnesium. 47 Cropp showed in dogs that there was a pronounced rise in pulmonary vascular resistance during hypoxia with normal concentrations of magnesium in the blood. As the magnesium concentrations were increased, the rise in pulmonary vascular resistance during hypoxia decreased. Hypoxic pulmonary vasoconstriction usually did not occur if magnesium rose above 5 mmol/l. Magnesium concentrations of less than 6-5 mmol/l did not cause hypotension or hypoventilation. He concluded that a controlled increase in the blood magnesium concentration to 5-6 mmol/l will block hypoxic pulmonary vasoconstriction without causing deleterious changes in haemodynamics or pulmonary ventilation. Attempts to use magnesium to decrease the pulmonary hypertension that was induced by hypoxia were not investigated in these studies. 2 Paidas et al showed that continuous infusion of ATP and magnesium chloride produced a significant decrease in mean pulmonary artery pressure after induced hypoxia with little or no systemic side effects. They also reported that magnesium chloride had no effect when infused alone. 53 The doses of magnesium chloride given were small and the concentrations in serum were not measured. It is well known that a slight or moderate rise in blood magnesium does not affect the circulation. This study did, however, show the effect that magnesium preparations had in reducing pulmonary arterial pressure and resistance, and their likely useful therapeutic effect in pulmonary hypertension syndromes, but it failed to show the effect of magnesium alone because of the study design. Oral treatment with magnesium aspartate hydrochloride has been shown by Mathew et al to attenuate monocrotaline induced pulmonary hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature in Wistar and Spraque-Dawley rats.54 Abu-Osba et al showed in a placebo controlled study of anaesthetised and ventilated sheep that during induced hypoxia (by breathing 10% oxygen) a sharp increase in the mean (SD) pulmonary artery pressure occurred from 16 (2-8) to 26 (5-3) mm Hg.55
During hypoxia there was no change in pulmonary arterial pressure (27 (5-7) mm Hg) after a placebo had been given. In contrast there was a sharp decrease after magnesium sulphate infusion (dose 200 mg/kg, serum concentration 2-88 mmol/1) in the right atrium; mean pulmonary arterial pressure was 25 (5 7) and 17 (5 6) mm Hg before and after treatment, respectively, p<0001. There was no change in the cardiac output and a transient decrease in the heart rate.
In severely sick infants born at full term with persistent pulmonary hypertension of the newborn and who did not respond to conventional treatment for 46-72 hours, magnesium sulphate was used as a vasodilator, a muscle relaxant, and a sedative (YK Abu-Osba et al, abstract presented at Paediatric Research Society Meeting, Leeds, March 1989).56 No other drugs were given or changes in the respirator settings or fractional inspiratory oxygen (F,02) were made after the magnesium sulphate had been given unless oxygen tension rose; F,02 and respirator settings were then reduced. Four infants had A-aDO2 gradients of over 84 5, and one had an A-aDO2 of 819 kPa, with predicted mortalities of 100% and 94%, respectively. After treatment with magnesium sulphate, mean (SD) oxygen tensions and haemoglobin oxygen saturation increased significantly within six hours from 4-3 (19) to 11-8 (7-6) kPa, p<0 04, and 58 (30) to 95 (5)%, respectively (p<003). One infant died with a persistent A-aDO2 of over 84-5 kPa. None had intraventricular haemorrhage, bronchopulmonary dysplasia, or bradycardia requiring intervention.
These studies show that magnesium is beneficial in reducing hypoxia induced pulmonary hypertension in both animals and in full term infants with persistent pulmonary hypertension of the newborn. Its efficacy in preterm infants and for other non-hypoxic causes of pulmonary hypertension should be investigated. Some reports have described a beneficial vasodilating effect together with reduction of complications after ischaemic hypoxia in the central nervous system, heart, kidneys, and liver.45 '' These conditions frequently coexist with pulmonary hypertension and severe hypoxaemia in neonates. Though a controlled multi-centre large study is required before recommending magnesium as a first line of treatment, these studies suggest its possible benefits in persistent pulmonary hypertension of the newborn when conventional treatment has failed, is contraindicated, or is unavailable. Close monitoring of blood pressure, kidney function, glucose calcium concentrations should be undertaken. Long term follow up is needed.
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